Historical Stock Chart
2 Months : From Dec 2019 to Feb 2020
By Colin Kellaher
AstraZeneca PLC (AZN, AZN.LN) and Merck & Co. (MRK) Monday said the U.S. Food and Drug Administration accepted and granted priority review to a supplemental new-drug application for Lynparza in combination with bevacizumab in advanced ovarian cancer.
The drugmakers said the filing covers the maintenance treatment of women with advanced ovarian cancer whose disease showed a complete or partial response to first-line treatment with platinum-based chemotherapy and bevacizumab.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.
AstraZeneca and Merck, which in 2017 formed a collaboration to co-develop and co-commercialize AstraZeneca's Lynparza for multiple cancer types, said the agency has set a target action date for the second quarter.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
January 13, 2020 07:28 ET (12:28 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.